Reglagene is advised by drug discovery and development professionals with exceptional track records of advancing new cancer medicines into the clinic and onto the market.
DAVID BEARSS, PhD
Dr. Bearss is the CEO at Tolero Pharmaceuticals in Salt Lake City, UT. He brings a consistent and successful track record of drug discovery and development that spans the last 17 years in both academic and industrial settings. Dr. Bearss is an expert in small-molecule drug development and in the use of genetic model systems in drug discovery, and he has deep experience in translational research focused on drug development and the use of genetic markers to predict drug sensitivity. He is also an expert in the development and use of genetically modified animals to model human disease. Dr. Bearss received his PhD in Cell and Structural Biology at the University of Texas Health Sciences Center at San Antonio and was a postdoctoral fellow with Dr. Daniel Von Hoff, a recognized leader in drug development. Dr. Bearss was on the faculty at the University of Arizona from 1999 to 2003, after which he cofounded Montigen Pharmaceuticals in 2003, where he served as Chief Scientific Officer until Montigen was acquired by SuperGen (Nasdaq: SUPG) in 2006. Dr. Bearss served as Chief Scientific Officer at SuperGen, overseeing early drug discovery and development and subsequently as Co-Director of the Center for Investigational Therapeutics at the Huntsman Cancer Institute, Associate Professor in the Department of Oncological Sciences at the University of Utah, and Associate Professor of Physiology & Developmental Biology at Brigham Young University prior to cofounding Tolero. Dr. Bearss has published more than 70 manuscripts and book chapters, has more than 30 patents issued or pending, and has won several awards for his scientific achievements. Dr. Bearss recently led Tolero to a successful $630M exit in an acquisition by Sumitomo Dainippon.
MARK CHAPMAN, PhD
Dr. Chapman is a veteran of large and small biotech companies. He is well versed in all aspects of drug discovery, from target selection, validation, screening, hit-to-lead, lead optimization, preclinical testing, candidate selection, and early clinical development. He has worked with small molecules as well as therapeutic antibodies. Mark has led cross-functional teams; established partnerships with CROs, clinicians, and academic groups; and is adept at addressing key questions in a cost-effective manner. He has deep knowledge in oncology and has additional experience in endocrinology and immunology. He holds a BA in genetics (UC Berkeley) and a PhD in Biochemistry (University of Arizona), and he trained at the Salk Institute.
Jim Heddles has 30 years of experience in preclinical drug discovery computing, having lead infrastructure and scientific projects and teams within Sanofi and its predecessor companies. Jim most recently had the privilege of leading a phenomenal IT/Informatics team through a complete rebuild of architecture, systems and applications after the acquisition of the Sanofi Tucson facility by Icagen. His passion is to help companies understand their workflows and data needs and adopt the most appropriate tools to enable excellent decision making for drug discovery.
MATTHEW MARX, PhD
Dr. Marx is the principal at Marx Pharma, LLC and a medicinal chemist with nearly 20 years of industry experience, mostly in the oncology therapeutic area. As a project scientist, project leader, or department head, he has been responsible for over 20 development candidates (Regulatory Toxicology candidates) and a dozen Initial New Drug applications. He completed his PhD in Organic Chemistry at the University of California at Berkeley and postdoctoral work at the University of Texas at Austin. His prior roles include Head of Oncology Chemistry at Pfizer’s Groton, CT site (1998–2010) and Chemistry Department Head at Takeda California (2010–2015). Dr. Marx currently is the Vice President of Discovery Chemistry for Mirati Therapeutics in San Diego. Dr. Marx is widely regarded in the Medicinal Chemistry community and is the outgoing chair of the Medicinal Chemistry Gordon Research Conference.
TERI SUZUKI, PhD
Teri has more than 20 years of Pharmaceutical R&D experience. She began her career at Selectide (later Sanofi), where she led pharmaceutical lead discovery projects that culminated in multiple advanced lead compounds, international patents, and clinical candidate compounds. She forged and led several innovative collaborations with academic groups, biotech companies, and larger partners, all based on the vision of mutual benefit. Her areas of expertise are the identification of drug leads and lead compound progression. She holds undergraduate degrees in chemistry and biochemistry and a PhD in biochemistry (University of Arizona). She is an Angel Investor with Tucson’s Desert Angels and serves on the External Advocacy Board for the University of Arizona’s Mathematics Department and the External Advisory Board for the University of Arizona’s Undergraduate Biology Research Program.
DANIEL VON HOFF, MD, FACP
Dr. Von Hoff, MD, FACP, is Physician-in-Chief and Distinguished Professor of Translational Research at the Translational Genomics Research Institute (TGen) in Phoenix, Arizona. He is also Senior Consultant, Clinical Investigations for the City of Hope; Chief Scientific Officer for HonorHealth Research Institute; Medical Director of Research, Chief Scientific Officer, US Oncology; and Professor of Medicine, Mayo Clinic. Dr. Von Hoff’s major interest is in the development of new anticancer agents, in both the clinic and the laboratory. He and his colleagues were involved in the beginning of the development of many of the agents we now use routinely, including mitoxantrone, fludarabine, paclitaxel, docetaxel, gemcitabine, irinotecan, nelarabine, capecitabine, lapatinib, vismodegib, nab-paclitaxel, nal-IRI, and others. At present, he and his colleagues are concentrating on the development of molecularly targeted therapies for patients with pancreatic and other advanced cancers. Dr. Von Hoff has published more than 690 papers, 140 book chapters, and over 1400 abstracts. Dr. Von Hoff received the 2010 David A. Karnofsky Memorial Award from the American Society of Clinical Oncology for his outstanding contributions to cancer research leading to significant improvement in patient care. Dr. Von Hoff was appointed to President Bush's National Cancer Advisory Board (2004–2010). Dr. Von Hoff is the past President of the American Association for Cancer Research (the world’s largest cancer research organization), a Fellow of the American College of Physicians, and a member and past board member of the American Society of Clinical Oncology. He is a founder of ILEX Oncology, Inc. (acquired by Genzyme after ILEX had two agents, alemtuzumab and clofarabine, approved by the FDA for patients with leukemia). Dr. Von Hoff is founder and Editor Emeritus of Investigational New Drugs, The Journal of New Anticancer Agents and past Editor-in-Chief of Molecular Cancer Therapeutics. He is a cofounder of the AACR/ASCO Methods in Clinical Cancer Research Workshop. He is also proud to have been a mentor and teacher for multiple medical students, medical oncology fellows, graduate students, and postdoctoral fellows.
1703 E Mabel St | Tucson, AZ 85721 | USA